Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
about
Rituximab: mechanism of actionTargeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalDysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsAntibody-based immunotherapy of solid cancers: progress and possibilitiesMechanisms of action of therapeutic antibodies for cancerDexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsAntigenic modulation and rituximab resistance.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphomaPutative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patientsPractical considerations on the use of rituximab in autoimmune neurological disordersRegulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphomaOncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Building better monoclonal antibody-based therapeutics.Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximabRituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptorsMacrophages are critical effectors of antibody therapies for cancerFludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Monoclonal antibody-induced cytokine-release syndrome.New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Rituximab: emerging treatment strategies of immune-mediated glomerular disease.Monoclonal antibodies in oncology therapeutics: present and future indications.Three major uncertainties in the antibody therapy of cancer.Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with RituximabImpact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo.Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor CellsAnti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.Near infrared photoimmunotherapy of B-cell lymphoma.Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells.The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma.Complement and cellular cytotoxicity in antibody therapy of cancerOfatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent CytotoxicityAnalysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
P2860
Q24607358-9BAC557F-200E-4215-A517-38688FBEED23Q24681992-D36ED8BA-8A28-4ABE-B64E-6C1701FDB4B4Q26771367-E67D381D-8FFF-4817-A30B-41C2E70A25B9Q26796542-E833E7DD-FC9D-4633-8F3F-B6738D3ED87EQ28385366-40F10820-89B2-4AA7-B8D9-5818AE92DA95Q28829762-6E39EAFD-1A81-4A5B-896B-578BA6B89482Q30421637-1A71EF86-30B1-4CB5-82E5-6E0346C46AC9Q30432874-6BE59B92-5876-4294-A30F-1481193560D6Q30439017-79C5BCEE-C6A7-4B25-A7B1-AAFDFC057865Q33380175-E4852177-5AC8-4DAD-BC11-8231ACE46D16Q33400351-AF2B63AA-B776-4D4D-B1AB-C2274A5D4549Q33621891-3F3B8DB7-A1CD-46E6-A162-86152F2CD07DQ34409447-5DF209DB-C788-46C1-A55C-68AB0793AFA0Q35783537-BBDB03B7-0D0F-470A-A0F1-53C5F376B035Q35812675-E0775CFC-CAD0-4C0D-A5B8-F5C21F581AACQ35817552-AA2B053A-F975-44A9-AE2A-98CEF845DBAEQ35911656-5690B0F4-73F9-4782-8AFD-DC0C5F806DD1Q36102906-4835BEE5-A571-419E-8ED8-06DEEAFFF39AQ36213288-AE3D390C-79B6-4B67-ABB2-83CF58B3D142Q36311218-7BB6B5A5-AFED-4358-80EF-9974629E3FC0Q37755276-114CE0EA-62FE-472F-9640-559E32E3692EQ37810901-8AC6D0D5-7A57-4F16-B07D-515E8BED61B6Q37913356-FD381B1B-78F6-49B2-92C6-DEACFEC2BF71Q38033648-5B582CAF-8D97-4338-B5BC-669094561BEAQ38071374-EB7B5F56-028A-452F-8EAE-930C5B80AA17Q38255786-13842988-73DA-40F9-B26D-98E3A3DC48FDQ38260684-110F5E53-07A3-4D7A-8FC1-82088EA58BE3Q38601426-670D5CF4-1B64-4F18-A647-646E6271FCA0Q38708447-8BA7245F-426E-49AC-AC5F-A4ED1A3B5E3AQ38733785-2615A696-D704-45A4-B25F-8A36B8A5F1ADQ38768387-09A3C360-94E5-41A4-9E84-883945EAD834Q38970811-B26D9A72-77A7-4E10-ACF7-83AF70AB26D6Q39646209-0624A856-7ED0-4EFD-AD19-5A30150A5542Q41480989-03164C34-EA5F-4BC0-871B-A1E4C35CABA3Q42060871-06ACCF04-08F4-4E97-AB94-63B8A632920FQ53141508-E1020B5C-0B6C-428A-BB35-34CD94303692Q56656130-67AAC808-BA79-4993-8C4B-EB3109CBC22EQ56908538-B6E45E29-9932-450E-953A-2E5ECFD5C6CAQ57583335-673BA7E4-B8F9-4EC4-AD2A-642C89EA7359
P2860
Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Ex vivo-activated human macrop ...... ity and impact of human serum.
@en
type
label
Ex vivo-activated human macrop ...... ity and impact of human serum.
@en
prefLabel
Ex vivo-activated human macrop ...... ity and impact of human serum.
@en
P2093
P921
P1476
Ex vivo-activated human macrop ...... city and impact of human serum
@en
P2093
Alessandra Nardin
Margarita Salcedo
Marie-Laure Lefebvre
P304
P356
10.1097/01.CJI.0000203081.43235.D7
P577
2006-07-01T00:00:00Z